Details for Patent: 10,392,406
✉ Email this page to a colleague
Which drugs does patent 10,392,406 protect, and when does it expire?
Patent 10,392,406 protects XOFLUZA and is included in two NDAs.
This patent has eighty-six patent family members in thirty-nine countries.
Summary for Patent: 10,392,406
| Title: | Substituted polycyclic pyridone derivatives and prodrugs thereof |
| Abstract: | The present invention provides the following compounds having anti-viral activity. |
| Inventor(s): | Makoto Kawai |
| Assignee: | Shionogi and Co Ltd |
| Application Number: | US15/569,191 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,392,406 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 10,392,406
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | XOFLUZA | baloxavir marboxil | FOR SUSPENSION;ORAL | 214410-001 | Nov 23, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Genentech Inc | XOFLUZA | baloxavir marboxil | FOR SUSPENSION;ORAL | 214410-002 | May 30, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Genentech Inc | XOFLUZA | baloxavir marboxil | FOR SUSPENSION;ORAL | 214410-003 | May 30, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Genentech Inc | XOFLUZA | baloxavir marboxil | TABLET;ORAL | 210854-001 | Oct 24, 2018 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Genentech Inc | XOFLUZA | baloxavir marboxil | TABLET;ORAL | 210854-002 | Oct 24, 2018 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Genentech Inc | XOFLUZA | baloxavir marboxil | TABLET;ORAL | 210854-003 | Mar 18, 2021 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,392,406
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2015-090909 | Apr 28, 2015 |
| Japan | 2015-236844 | Dec 3, 2015 |
| PCT Information | |||
| PCT Filed | April 27, 2016 | PCT Application Number: | PCT/JP2016/063139 |
| PCT Publication Date: | March 11, 2016 | PCT Publication Number: | WO2016/175224 |
International Family Members for US Patent 10,392,406
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3428170 | ⤷ Start Trial | LUC00198 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 3428170 | ⤷ Start Trial | C20210003 00390 | Estonia | ⤷ Start Trial |
| European Patent Office | 4219508 | ⤷ Start Trial | 122024000036 | Germany | ⤷ Start Trial |
| European Patent Office | 4219508 | ⤷ Start Trial | 301295 | Netherlands | ⤷ Start Trial |
| European Patent Office | 4219508 | ⤷ Start Trial | 2024C/542 | Belgium | ⤷ Start Trial |
| European Patent Office | 4219508 | ⤷ Start Trial | C20240038 | Finland | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
